SOURCE: Vitro Diagnostics, Inc.

September 25, 2007 08:00 ET

Vitro Announces Construction of a New Manufacturing Facility

AURORA, CO--(Marketwire - September 25, 2007) - Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced the beginning of construction of build-to-suit corporate headquarters in Golden Colorado. The new facility is located in the Coors Technology Center and will be used for manufacturing, research & development and administrative functions. It is designed to support manufacturing of the Company's human stem cell products for various commercial applications in medical research, pharmaceutical manufacturing and potentially for cell therapy of diabetes. The new facility is especially suited for FDA-compliant manufacturing in a modern and extensively controlled environment. The Company plans to lease the facility from a third party.

Dr. Jim Musick, Vitro's President and CEO, said, "We are very pleased to announce the beginning of construction of the new facility. While our present facility was adequate for R&D, we now require an expanded facility to provide stem cell products for medical applications that are manufactured to stringent specifications. We anticipate that the new corporate facility will allow expanded production of our stem cell-based products targeting specific markets in medical research, drug development and discovery."

About Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc. dba Vitro Biopharma (OTCBB: VODG) http://www.vitrodiag.com, has generated over 30 adult pancreatic stem cell lines that are distinct from the limited number of embryonic stem cell lines that are presently approved for federally funded research. These cell lines may have commercial application in drug development and discovery, diabetes research and therapy. The Company developed and manufactures the VITROCELL™ brand of human cell lines consisting of pancreatic-derived cell lines and related products that are sold for various research and commercial applications.

Safe Harbor Statement

Certain statements contained herein and subsequent oral statements made by and on behalf of the Company may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's Annual Report on Form 10-KSB for the fiscal year ended October 31, 2004 under the caption, "Risk Factors." Most these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • CONTACT:
    Dr. James Musick
    Chief Executive Officer
    Vitro Diagnostics, Inc.
    (720) 859-4120
    E-mail: Email Contact